In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

The man had 'tried everything' before Mounjaro gave him a 'life-saving' change, leading to an incredible nine stone weight ...

Mounjaro is one of the bestselling weight loss drugs. See what your options are if you want to invest in Mounjaro stock.

Women's health doctor Ravina Bhanot, from Zonas Fertility, told LADbible: "Hair loss while taking Mounjaro is a common side effect due to rapid weight loss. It is more likely linked to caloric ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Eli Lilly and Novo Nordisk intensify their weight-loss drug rivalry in India as rising demand and looming generics reshape a ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...